

17 October 2008

The Manager  
Company Announcements Office  
Australian Securities Exchange Limited  
20 Bridge Street  
Sydney NSW 2000



**cyclo**medica  
**molecula**r imaging  
**techn**egas

Cyclopharm Limited  
ABN 74 116 931 250  
Suite 630 Level 6  
1 Queens Road  
Melbourne Victoria 3004  
Australia  
T 61 3 9867 2811  
F 61 3 9820 5957  
[www.cyclopharm.com](http://www.cyclopharm.com)

### **Amended Rights Issue Timetable**

Following a request from the Australian Securities Exchange we have amended the Rights Issue Timetable.

Please refer to the amended Appendix 3B that follows.

William Richardson  
**Company Secretary**

### **Contact details:**

William Richardson  
Company Secretary  
T: +61 3 9867 2811

# Appendix 3B

## New issue announcement, application for quotation of additional securities and agreement

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003, 24/10/2005.

Name of entity

CYCLOPHARM LIMITED

ABN

74 116 931 250

We (the entity) give ASX the following information.

### Part 1 - All issues

*You must complete the relevant sections (attach sheets if there is not enough space).*

- |   |  |                            |
|---|--|----------------------------|
| 1 | +Class of +securities issued or to be issued   | Ordinary Shares            |
| 2 | Number of +securities issued or to be issued (if known) or maximum number which may be issued  | 31,800,000                 |
| 3 | Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion) | Fully paid ordinary shares |

+ See chapter 19 for defined terms.

**Appendix 3B**  
**New issue announcement**

---

| <p>4 Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?</p> <p>If the additional securities do not rank equally, please state:</p> <ul style="list-style-type: none"> <li>• the date from which they do</li> <li>• the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul> | <p>Yes</p>  |        |        |             |                 |
|--|---|--------|--------|-------------|-----------------|
| <p>5 Issue price or consideration</p>  | <p>\$0.10 per share</p>   |        |        |             |                 |
| <p>6 Purpose of the issue<br/>         (If issued as consideration for the acquisition of assets, clearly identify those assets)</p>   | <p>To part fund the capital expenditure program for the Company's Molecular Imaging division.</p>   |        |        |             |                 |
| <p>7 Dates of entering +securities into uncertificated holdings or despatch of certificates</p>  | <p>Estimated to be 28 November 2008</p>   |        |        |             |                 |
| <p>8 Number and +class of all +securities quoted on ASX (including the securities in clause 2 if applicable)</p>   | <table border="1"> <thead> <tr> <th data-bbox="721 1484 995 1514">Number</th> <th data-bbox="1000 1484 1266 1514">+Class</th> </tr> </thead> <tbody> <tr> <td data-bbox="721 1520 995 1549">171,012,616</td> <td data-bbox="1000 1520 1266 1549">Ordinary shares</td> </tr> </tbody> </table> | Number | +Class | 171,012,616 | Ordinary shares |
| Number   | +Class  |        |        |             |                 |
| 171,012,616  | Ordinary shares   |        |        |             |                 |

---

+ See chapter 19 for defined terms.

|   | Number | +Class |
|---|--------|--------|
| 9 Number and +class of all +securities not quoted on ASX (including the securities in clause 2 if applicable) | Nil    | N/A    |

|   |  |
|---|--|
| 10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests) | Identical to existing quoted ordinary shares |
|---|--|

## Part 2 - Bonus issue or pro rata issue

|  |    |
|--|----|
| 11 Is security holder approval required? | No |
|--|----|

|   |                  |
|---|------------------|
| 12 Is the issue renounceable or non-renounceable? | Non-renounceable |
|---|------------------|

|   |         |
|---|---------|
| 13 Ratio in which the +securities will be offered | 1 : 4.4 |
|---|---------|

|   |                 |
|---|-----------------|
| 14 +Class of +securities to which the offer relates | Ordinary shares |
|---|-----------------|

|   |                 |
|---|-----------------|
| 15 +Record date to determine entitlements | 27 October 2008 |
|---|-----------------|

|   |     |
|---|-----|
| 16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements? | N/A |
|---|-----|

|  |               |
|--|---------------|
| 17 Policy for deciding entitlements in relation to fractions | Rounded down. |
|--|---------------|

|  |   |
|--|---|
| 18 Names of countries in which the entity has +security holders who will not be sent new issue documents<br><br><small>Note: Security holders must be told how their entitlements are to be dealt with.<br/>Cross reference: rule 7.7.</small> | Only Australian and New Zealand registered security holders will be allowed to participate in the rights issue. |
|--|---|

|   |                  |
|---|------------------|
| 19 Closing date for receipt of acceptances or renunciations | 21 November 2008 |
|---|------------------|

+ See chapter 19 for defined terms.

**Appendix 3B**  
**New issue announcement**

|    |   |  |
|----|---|--|
| 20 | Names of any underwriters   | CVC Venture Managers Pty Ltd   |
| 21 | Amount of any underwriting fee or commission  | 4% of the amount raised plus an administration and handling fee of 0.5% of amount raised |
| 22 | Names of any brokers to the issue   | N/A  |
| 23 | Fee or commission payable to the broker to the issue  | N/A  |
| 24 | Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of <sup>+</sup> security holders                             | N/A  |
| 25 | If the issue is contingent on <sup>+</sup> security holders' approval, the date of the meeting  | N/A  |
| 26 | Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled  | 30 October 2008  |
| 27 | If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders | N/A  |
| 28 | Date rights trading will begin (if applicable)  | N/A  |
| 29 | Date rights trading will end (if applicable)  | N/A  |
| 30 | How do <sup>+</sup> security holders sell their entitlements <i>in full</i> through a broker?   | N/A  |
| 31 | How do <sup>+</sup> security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?                                    | N/A  |

+ See chapter 19 for defined terms.

- 
- 32 How do <sup>+</sup>security holders dispose of their entitlements (except by sale through a broker)? N/A
- 33 <sup>+</sup>Despatch date 28 November 2008

### Part 3 - Quotation of securities

*You need only complete this section if you are applying for quotation of securities*

- 34 Type of securities  
(tick one)
- (a)  Securities described in Part 1
- (b)  All other securities  
Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

#### Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

*Tick to indicate you are providing the information or documents*

- 35  If the <sup>+</sup>securities are <sup>+</sup>equity securities, the names of the 20 largest holders of the additional <sup>+</sup>securities, and the number and percentage of additional <sup>+</sup>securities held by those holders  
**TBA**
- 36  If the <sup>+</sup>securities are <sup>+</sup>equity securities, a distribution schedule of the additional <sup>+</sup>securities setting out the number of holders in the categories  
1 - 1,000  
1,001 - 5,000  
5,001 - 10,000  
10,001 - 100,000  
100,001 and over  
**TBA**
- 37  A copy of any trust deed for the additional <sup>+</sup>securities

---

<sup>+</sup> See chapter 19 for defined terms.

**Appendix 3B**  
**New issue announcement**

---

**Entities that have ticked box 34(b)**

38 Number of securities for which  
 +quotation is sought

39 Class of +securities for which  
 quotation is sought

40 Do the +securities rank equally in  
 all respects from the date of  
 allotment with an existing +class  
 of quoted +securities?

If the additional securities do not  
 rank equally, please state:

- the date from which they do
- the extent to which they  
 participate for the next  
 dividend, (in the case of a  
 trust, distribution) or interest  
 payment
- the extent to which they do  
 not rank equally, other than in  
 relation to the next dividend,  
 distribution or interest  
 payment

41 Reason for request for quotation  
 now

Example: In the case of restricted securities, end  
 of restriction period

(if issued upon conversion of  
 another security, clearly identify  
 that other security)

|  | Number | +Class |
|--|--------|--------|
| 42 Number and +class of all<br>+securities quoted on ASX<br>(including the securities in clause<br>38) |        |        |

---

+ See chapter 19 for defined terms.

**Quotation agreement**

- 1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.
  
- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  
  - There is no reason why those +securities should not be granted +quotation.
  
  - An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.  
Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty
  
  - Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
  
  - If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.
  
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
  
- 4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.



Sign here: .....Date: 17 October 2008  
(~~Director~~/Company secretary)

Print name: William Richardson  
== == == == ==

---

+ See chapter 19 for defined terms.